|
|
| | KRAS G12D inhibitor 24 Basic information |
| | KRAS G12D inhibitor 24 Chemical Properties |
| Boiling point | 771.7±70.0 °C(predicted) | | density | 1.43±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 8.05±0.40(predicted) |
| | KRAS G12D inhibitor 24 Usage And Synthesis |
| Uses | KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC50 of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity[1]. | | References | [1] Tyligand Bioscience (Shanghai) Limited. Quinazoline compounds as KRAS inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. World Intellectual Property Organization, WO2024067714 A1 2024-04-04 |
| | KRAS G12D inhibitor 24 Preparation Products And Raw materials |
|
|
Tag:KRAS G12D inhibitor 24(3033701-29-7)
Related Product Information
|
|
2,7-Diazaspiro[4.4]nonane-2-acetamide, α-cyclopentyl-7-[[(2R,3R)-3-cyclopropyl-1-methyl-2-aziridinyl]carbonyl]-N-[(1R,10S,12S,18S)-1-[5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-2,7,8,10,11,12,13,16,17,18,19,21,22,23-tetradecahydro-22,22-dimethyl-13,19-dioxo-2-(2,2,2-trifluoroethyl)-15H-3,5-etheno-14,18-imino-6,10-methano-6H-pyrrolo[3,4-g][1,12,4,18]dioxadiazacyclodocosin-12-yl]-, (αS,5S)-
NAV2729
Y-27632
1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro-
EHT1864
RMC5127
|